Get started
Author

Natalie Zarabi

Observed name: N Zarabi
Institution: MSD (Sweden)
Observed institution: MSD (Sweden)
ORCID: 0000-0003-1004-320X
Observed ORCID: 0000-0003-1004-320X
OpenAlex ID: A5062261663
Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy
2018 · Karl Patterson, Vimalanand Prabhu, et al. · European Urology Oncology · 28
PDF
Cost-Effectiveness of School-Based Prevention of Cannabis Use
2015 · Charlotte Deogan, Natalie Zarabi, et al. · Applied Health Economics and Health Policy · 20
Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden
2018 · Tushar Srivastava, Vimalanand S. Prabhu, et al. · European Urology Oncology · 17
PDF
Clinical and economic burden of pneumococcal disease among adults in Sweden: A population-based register study
2023 · Natalie Zarabi, Martina Aldvén, et al. · PLoS ONE · 15
PDF
Parental acceptance and knowledge of varicella vaccination in relation to socioeconomics in Sweden: A cross-sectional study
2021 · Lisen Arnheim-Dahlström, Natalie Zarabi, et al. · PLoS ONE · 11
PDF
EPH120 Clinical and Economic Burden of Severe Pneumococcal Disease Among Adults in Sweden: A Population-Based Register Study
2022 · N Zarabi, M Aldvén, et al. · Value in Health
PDF
Works count: 6
Citation count: 91
H-index: 5
I10-index: 5
Year
Topic
Type